Amedica, Corp. (NASDAQ:AMDA) Receives Positive Nasdaq Listing Decision, Share Price Explodes

Innovative biomaterial company that develops and manufactures silicon nitride as a platform for biomedical applications, Amedica, Corp. (NASDAQ:AMDA), has announced that the Nasdaq Hearings Panel has granted its request for an extension to provide evidence of full compliance.

SALT LAKE CITY, Oct. 17, 2017 (GLOBE NEWSWIRE) — Amedica Corporation (AMDA) (the “Company”), an innovative biomaterial company that develops and manufactures silicon nitride as a platform for biomedical applications, announced today that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for an extension within which to evidence full compliance with the criteria for continued listing on The Nasdaq Capital Market, including the filing requirement and the $1.00 closing bid price requirement. The Company’s continued listing on Nasdaq is subject to the Company filing its Forms 10-Q for the quarterly periods ended March 31, 2017 and June 30, 2017 with the SEC by October 31, 2017, and the Company evidencing a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days by November 30, 2017. The Company expects to timely satisfy the deadlines set forth in the Panel’s decision.

The Company is diligently working to evidence full compliance with all applicable requirements for continued listing on The Nasdaq Capital Market; however, there can be no assurance that the Company will regain compliance with the applicable criteria within the period of time granted by the Panel.

About Amedica Corporation

Amedica is focused on the development and application of medical-grade silicon nitride ceramics. Amedica markets spinal fusion products and is developing a new generation of wear- and corrosion-resistant implant components for hip and knee arthroplasty. The Company manufactures its products in its ISO 13485 certified manufacturing facility and, through its partnership with Kyocera, the world’s largest ceramic manufacturer. Amedica’s spine products are FDA-cleared, CE-marked, and are currently marketed in the U.S. and select markets in Europe and South America through its distributor network and its OEM partnerships.

For more information on Amedica or its silicon nitride material platform, please visit www.amedica.com.

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties. For example, there can be no assurance that we will regain compliance with the applicable criteria within the period of time granted by the Panel and that we will be able to maintain our listing on any NASDAQ market.  Other factors that could cause actual results to differ materially from those contemplated within this press release can also be found in Amedica’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on September 20, 2017, and in Amedica’s other filings with the SEC.  Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Original Source

Amedica, Corp. (NASDAQ:AMDA) shares are trading +20.328% on the news and in the range of $0.300 – 0.370 during the current trading session.  When taking a look at which direction the stock might be headed, investors often look to brokerage analysts who cover the stock.  Sell-side research firms on Wall Street currently have a consensus one-year price target of $3.250 on the stock.  This is according to brokerage analysts polled by Thomson Reuters First Call.

Are Shares of Amedica, Corp. (NASDAQ:AMDA) Ready to Explode?  Sign up to our Newsletter to be the First to Know 

Sign up to get our Free Penny Stock Picks Before the Street!

Sell-side analysts are projecting earnings per share of $-0.080 for the next fiscal quarter.  For the current year, analysts are predicting earnings of $-0.240 per share according to First Call.

In looking at where the stock is trading on a technical level, the stock is trading +18.365% away from its 50-day moving average of $0.310.  Based on the most recent available data, the equity is -66.330% off of its 52-week high of $1.090 and +39.969% away from its 52-week low which is $0.262.

Today, the stock opened at $0.309 and the last bid at the time of writing stood at $0.367.  During the session thus far, the equity dipped down to $0.300 and touched $0.370 as the high point.  Amedica, Corp. (NASDAQ:AMDA) has a market cap of $13.31M and has seen an average daily volume of 249,134 over the past three months.

Sign Up to Receive Breaking Alerts on Stocks That Are Primed to Make a Run in the Bar Below. 

Sign up to get our Free Penny Stock Picks Before the Street!

Disclaimer: Nothing contained in this publication is intended to constitute legal, tax, securities, or investment advice, nor an opinion regarding the appropriateness of any investment, nor a solicitation of any type. The general information contained in this publication should not be acted upon without obtaining specific legal, tax, and investment advice from a licensed professional.

Leave a Comment